4th Quarter - Amendment

INFECTIOUS DISEASES SOCIETY OF AMERICA for INFECTIOUS DISEASES SOCIETY OF AMERICA

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$115,820
Expense method
C: businesses, Internal Revenue Code section 162(e)

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 16, 2009 $116,112 Replaced
4th Quarter - Report Jan 20, 2010 $115,820 Replaced
4th Quarter - Amendment (this page) Jan 20, 2010 $115,820 Replaced
4th Quarter - Amendment Jun 22, 2010 $115,820 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Reimbursement for outpatient infusion therapy; Physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; and Healthcare Reform.

LobbyistCovered position, as disclosed
ROBERT J GUIDOS V.P. Public Policy & Government Relations
KIMBERLY ANN MILLER HIV Medicine Association Policy Officer
R MICHAEL OCHS Government Relations Associate
JASON SCULL Program Officer for Clinical Affairs
ANDREA WEDDLE Executive Director, HIV Medicine Association

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); Centers For Disease Control & Prevention (CDC); SENATE; Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); U.S. Agency for International Development (USAID)

Health Issues HCR

Infectious Diseases; drug and vaccine research and development; antimicrobial resistance; hospital-acquired infections; immunizations; pandemic influenza, public health security and biodefense; global infectious diseases; biomedical research, reauthorization of President's Emergency Plan for AIDS Relief (PEPFAR); Lyme disease and other infectious diseases issues; Ryan White reauthorization; Strategies to Address Antimicrobial Resistance Act.

LobbyistCovered position, as disclosed
ROBERT J GUIDOS V.P. Public Policy & Government Relations
KIMBERLY ANN MILLER HIV Medicine Association Policy Officer
R MICHAEL OCHS Government Relations Associate
ANDREA WEDDLE Executive Director, HIV Medicine Association

Contacted: SENATE; U.S. Agency for International Development (USAID); Health Resources & Services Administration (HRSA); Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Budget/Appropriations BUD

Funding support for the Depatment of Health and Human Services, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources & Services Administration, Food & Drug Administration and global programs for various infectious diseases related issues.

LobbyistCovered position, as disclosed
ROBERT J GUIDOS V.P. Public Policy & Government Relations
KIMBERLY ANN MILLER HIV Medical Association Policy Officer
R MICHAEL OCHS Government Relations Associate
ANDREA WEDDLE Executive Director, HIV Medical Association

Contacted: Health Resources & Services Administration (HRSA); Natl Institutes of Health (NIH); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; U.S. Agency for International Development (USAID); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); SENATE; Food & Drug Administration (FDA)

Medical/Disease Research/Clinical Labs MED

Medical liability; Antimicrobial resistance research; Infectious diseases product research and development; Unnecessary regulatory burdens places on medical research; Support for evidence-based decision making.

LobbyistCovered position, as disclosed
ROBERT J GUIDOS V.P. Public Policy & Government Relations
KIMBERLY ANN MILLER HIV Medicine Association Policy Officer
R MICHAEL OCHS Government Relations Associate
ANDREA WEDDLE Executive Director, HIV Medical Association

Contacted: U.S. Agency for International Development (USAID); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; Health Resources & Services Administration (HRSA); Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA)

Affiliated organisations

OrganisationLocation
HIV MEDICINE ASSOCIATION Arlington, VA, US

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.